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four with a signiﬁcant increase in ARP, and two with a signiﬁcant
increase in OPC (p < 0.05). By comparison, Medicare Part D
resulted in signiﬁcant TRx increases for ten drugs (and no
decreases), eight showed ARP increases and two had ARP
decreases (p < 0.05). Interestingly, seen drugs decreased OPC
while two increased (p < 0.05). CONCLUSIONS: NICE HTAs
had mild effects on the prescription utilization and costs in the
US, while Medicare Part D caused fundamental changes to the
market parameters measured. The inﬂuence of NICE decisions
on the US market should be monitored as HTAs are expected to
play a more signiﬁcant role in the advent of Medicare Part D
Reimbursement.
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OBJECTIVES: Health technology assessment is used to inform
reimbursement decisions for pharmaceuticals in many countries.
The political and administrative contexts in which HTA is used
vary considerably between countries, as do the decisions on
individual products. The aim of this study was to investigate the
inﬂuence of HTA and other factors on reimbursement decisions.
METHODS: A systematic search was conducted to obtain the
documentation for reimbursement decisions on cancer and car-
diovascular medicines. Where insufﬁcient information was pub-
lished, or reports were not available in English, decisions were
excluded. The analysis was conducted using discrete response
models and included methods of assessment, evidence included
and stakeholder involvement. RESULTS: Detailed information
was obtained on 194 decisions from Australia, Belgium, Canada,
England, France, Scotland and Sweden. The pooled analysis
showed that 27% of medicines were recommended, 41% were
recommended for restricted use and 32%were not recommended.
The multinomial logistic regression showed that the number of
RCTs, disease area, use of sensitivity analysis and public interest
had a statistically signiﬁcant impact upon decisions. The use of
cost-utility analysis in the supporting HTA was found to reduce
the probability of a positive recommendation. The analysis for
those countries that included cost-utility analysis showed that the
value of the ICER had a statistically insigniﬁcant impact upon the
decision.However, a sub-analysis for decisions in England showed
that this was found to be statistically signiﬁcant. CONCLU-
SIONS:These ﬁndingsmay reﬂect varying approaches to conduct-
ing economic analysis, differences in cost-effectiveness thresholds
and variation in the weight given to economic evidence in inform-
ing decisions within countries. The individual product level
factors explain some of the variation in reimbursement decisions
across countries. Further variationmay be explained by the health
system and policy context in which decisions are made. The next
stage of the work will investigate these factors directly.
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OBJECTIVES: Early-stage medical technology assessment
(MTA) is sometimes conducted in an ad-hoc manner, if it is
performed at all. Identiﬁcation of universal steps in early-stage
MTA would catalyze the development of valuable technology.
METHODS: Universal steps in early-stage MTA were developed
following evaluation of a new stroke rehabilitation strategy tar-
geting the urban Chinese population. Literature review, physician
and patient interviews, and decision modelling were performed
to appraise current stroke care and evaluate methods to improve
it. Different rehabilitation strategies were recognised and
described, and their costs and health effects were estimated and
compared. RESULTS: Certain universal steps in early-stage MTA
could be identiﬁed. An important ﬁrst step is the creation of a
detailed study plan that includes evaluation criteria and may also
discuss the value of a disease progression model. A second step
consists of qualitative and quantitative descriptions of current
treatments and new technologies. This step focuses not simply
on acquiring quantitative estimates of costs, health effects and
quality of care, but also on identifying areas for quality improve-
ment. Since the literature review did not yield sufﬁcient informa-
tion, other methods (i.e., interviews) were needed to ascertain
attitudes regarding usual care and behaviour. These methods
provided extra insight into physician and patient preferences,
insight that was used to modify the evaluation criteria. Subse-
quently, the new technology was described both qualitatively and
quantitatively. Lastly, the costs and health effects of the treat-
ments were compared using standard techniques (e.g., uncer-
tainty analysis). These results identiﬁed where more information
needed to be collected. CONCLUSIONS: As with later-stage
MTA, there is a need and an opportunity to develop universal
steps for conducting early-stage MTA. They supplement, but do
not replace, the steps and techniques applied during later-stage
assessments. If properly formulated, they can be used to facilitate
good internal decision-making during the development phase.
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OBJECTIVES: In England only new innovative technologies
evaluated useful and cost effective are taken up by health care
providers. NICE leads the way for this managed entry, but delays
in publication of guidance, and the fact it only covers tech-
nologies with the potential to have large ﬁnancial impact, leaves
local payers looking to other technology appraisal groups for
guidance—often local groups, to review a technology in line with
local needs, demographics and priorities. There are more than 30
of these review groups operating in England, on either a national
or local level which inﬂuence prescribing, funding, and commis-
sioning decisions. This research was undertaken to understand,
and map the inﬂuence of these organizations. METHODS: A
total of 65 senior mangers from SHAs, PCTs, hospital Trusts, and
HTA organsiations were interviewed, using qualitative and quan-
titative measures, to provide an indication of the current, and
future inﬂuence of HTA organizations in England. RESULTS:
For interventions without forthcoming NICE guidance, NHS
organizations are responsible for accessing publicly available
evidence to determine local policies for managed entry. Notiﬁca-
tion of new drugs is generally from one of the national informa-
tion portals. In the absence of NICE guidance, the SMC is, for
most, the next port of call. If there is no NICE, or SMC guidance,
HCPs generally look to their regional group, or the HTA group
with relevant therapy experience. The remit, focus and inﬂuence
of the different regional groups was assessed and found to vary.
CONCLUSIONS: Because of delays in NICE guidance of up to
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